[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100096577":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":37,"centralContacts":27,"locations":41,"responsibleParty":87,"collaborators":27,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":27,"eligibilityCriteria":95,"healthyVolunteers":91,"sex":96,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":27,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":27,"overallStatus":108,"whyStopped":27,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"GlaxoSmithKline","INDUSTRY",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Cervarix Group","EXPERIMENTAL","Young adult women from the Brazilian cohort who participated in the primary study 580299\u002F001 (NCT00689741) and follow-up study 580299\u002F007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.",[13,14,15],"Procedure: Blood sampling","Procedure: Collection of cervical specimen","Biological: Cervarix",{"label":17,"type":18,"description":19,"interventionNames":20},"Placebo Group","PLACEBO_COMPARATOR","Young adult women from the Brazilian cohort who participated in the primary study 580299\u002F001 (NCT00689741) and follow-up study 580299\u002F007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.",[13,14],[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"PROCEDURE","Blood sampling","Blood sampling at Visit 3, 5 and 7.",[9,17],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Collection of cervical specimen","Collection of cervical specimen at Visit2, 3, 4, 5, 6 and 7.",[9,17],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":27},"BIOLOGICAL","Cervarix","Three doses administered intramuscularly at 0, 1 and 6 months.",[9],[38],{"name":39,"affiliation":5,"role":40},"GSK Clinical Trials","STUDY_DIRECTOR",[42,55,64,72,80],{"facility":43,"status":27,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":27},"GSK Investigational Site","Curitiba","Paraná","80069-900","Brazil","BR",{"type":50,"coordinates":51},"Point",[52,53],-49.27306,-25.42778,{"lat":53,"lon":52},{"facility":43,"status":27,"city":56,"state":57,"zip":58,"country":47,"countryCode":48,"cosmosGeoPoint":59,"geoPoint":63,"contacts":27},"Porto Alegre","Rio Grande do Sul","90035-903",{"type":50,"coordinates":60},[61,62],-51.23019,-30.03283,{"lat":62,"lon":61},{"facility":43,"status":27,"city":65,"state":65,"zip":66,"country":47,"countryCode":48,"cosmosGeoPoint":67,"geoPoint":71,"contacts":27},"São Paulo","03015000",{"type":50,"coordinates":68},[69,70],-46.63611,-23.5475,{"lat":70,"lon":69},{"facility":43,"status":27,"city":73,"state":27,"zip":74,"country":47,"countryCode":48,"cosmosGeoPoint":75,"geoPoint":79,"contacts":27},"Campinas","13083-970",{"type":50,"coordinates":76},[77,78],-47.06083,-22.90556,{"lat":78,"lon":77},{"facility":43,"status":27,"city":81,"state":27,"zip":27,"country":47,"countryCode":48,"cosmosGeoPoint":82,"geoPoint":86,"contacts":27},"Fortaleza",{"type":50,"coordinates":83},[84,85],-38.54306,-3.71722,{"lat":85,"lon":84},{"type":88,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100096577","phase-2-follow-up-study-to-evaluate-the-long-term-efficacy-of-the-hpv-vaccine-580299-in-healthy-young-adult-women-in-brazil-100096577",true,"NCT00518336","Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil","Follow-up Study to Evaluate the Long-term Efficacy of a HPV Vaccine (580299) in Healthy Young Adult Women in Brazil","Inclusion Criteria:\n\n* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.\n* Subjects who participated in study 580299-007.\n* Written informed consent obtained from the subject prior to enrollment.\n\nExclusion Criteria:\n\n* Use or planned use of any investigational or non-registered product other than the study vaccine.\n* Decoding of the subject's 580299-001 treatment allocation to either the subject or the investigator.\n* Administration or planned administration of any other HPV vaccine, other than the vaccine administered in study 580299-001.","FEMALE","15 Years","25 Years",{"count":100,"type":101},433,"ACTUAL","INTERVENTIONAL",[104],"PHASE2","Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. This Phase IIb study is designed to evaluate the the long-term efficacy, safety and immunogenicity of the 580299 HPV vaccine (CervarixTM) in a Brazilian cohort of women vaccinated in the phase IIb, blinded, primary study 580299\u002F001 (NCT00689741) and having participated in follow-up study 580299\u002F007 (NCT00120848). Only subjects who participated in the primary \\& follow-up study will be enrolled in this long-term follow-up study. Subjects were aged 15-25 years at the time of entry into the primary study.\n\nThe Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.",[107],"Infections, Papillomavirus","COMPLETED","2016-10-27",{"date":111,"type":112},"2016-12-09","ESTIMATED",{"date":114,"type":27},"2007-11",{"date":116,"type":101},"2010-09",{"name":5,"class":6},5]